Expertise in

conditions

Peter Dreger

Heidelberg, BW, DE

Expertise in

conditions

Heidelberg, BW, DE

Overview

Peter Dreger practices in Heidelberg, Germany. Mr. Dreger is highly rated in 31 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 376 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Heidelberg, BW, Germany

Other Locations

Heidelberg
Salem, BW, Germany

Halle, NI, Germany

Germany

Hamburg, HH, Germany

Feld, NW 69120, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Enrollment Status: Completed

Publish Date: December 01, 2025

Intervention Type: Biological, Drug

Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine

Study Phase: Phase 3

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Enrollment Status: Active_not_recruiting

Publish Date: April 20, 2025

Intervention Type: Drug

Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab

Study Phase: Phase 3

IDH2-Post-Allo-Trial: Enasidenib As Consolidation or Salvage Therapy for Patients with IDH2 Mutated AML or MDS Following Allogeneic Blood Stem Cell Transplantation

Enrollment Status: Completed

Publish Date: September 19, 2024

Intervention Type: Drug

Study Drug: Enasidenib

Study Phase: Phase 2

Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML

Enrollment Status: Completed

Publish Date: January 19, 2024

Intervention Type: Drug

Study Phase: Phase 3

A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Enrollment Status: Completed

Publish Date: May 24, 2023

Intervention Type: Drug, Diagnostic test, Procedure

Study Phase: Phase 2

Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens

Enrollment Status: Completed

Publish Date: July 30, 2020

Intervention Type: Drug

Study Phase: Phase 3

Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)

Enrollment Status: Terminated

Publish Date: December 02, 2019

Intervention Type: Drug

Study Phase: Phase 2

View 6 Less Clinical Trials

376 Total Publications

Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphoma.

Journal: Bone marrow transplantation

Published: August 25, 2025

View All 376 Publications

Frequently Asked Questions about Peter Dreger

Is Peter Dreger a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Peter Dreger is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Peter Dreger participate in research or clinical trials?

Yes. Peter Dreger has published 376 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Peter Dreger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dreger's expertise for a condition

ConditionClose